Dihydroquinoline pyrazolyl compounds

1. A compound of formula (I)

wherein

R 1 , R 5 , R 6 , R 7 and R 8 are independently selected from H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 2 , R 3 and R 4 are independently selected from H, halogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 9 is alkylsulfanylalkyl, alkylsulfonylalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, hetroarylalkyl, substituted heteroarylalkyl or the group A, wherein substituted aryl, substituted arylalkyl, substituted heteroaryl and substituted heteroarylalkyl are substituted with one to three substituents selected from the group consisting of alkyl, halogen, haloalkyl, cycloalkyl, halocycloalkyl, cyano, alkoxy, haloalkoxy, alkylsulfanyl, haloalkylsulfanyl, alkylsulfonyl and haloalkylsulfonyl;

R 10 is pyrazolyl, substituted pyrazolyl, pyridinyl or substituted pyridinyl, wherein substituted pyrazolyl and substituted pyridinyl are substituted with one to three substituents selected from the group consisting of alkyl, halogen, haloalkyl, cycloalkyl and halocycloalkyl;

R 15 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 16 and R 17 are independently selected from H, alkyl and cycloalkyl;

n is zero or 1;

or, pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 , wherein R 1 is alkyl.

3. The compound according to claim 1 , wherein R 5 , R 6 , R 7 and R 8 are H.

4. The compound according to claim 1 wherein R 2 and R 3 are H.

5. The compound according to claim 1 wherein R 4 is H or halogen.

6. The compound according to claim 1 , wherein R 4 is H.

7. The compound according to claim 1 wherein R 15 is H.

8. The compound according to claim 1 , wherein R 16 and R 17 are H.

9. The compound according to claim 1 wherein n is 0.

10. The compound according to claim 1 wherein R 1 is alkyl, R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 15 , R 16 and R 17 are H, R 4 is H or halogen and n is 0.

11. The compound according to claim 10 , wherein R 9 is alkylsulfanylalkyl, alkylsulfonylalkyl, substituted aryl, substituted arylalkyl or the group A, wherein substituted aryl and substituted arylalkyl are substituted with one to three substituents selected from alkyl, halogen, cyano, alkoxy, alkylsulfanyl and alkylsulfonyl.

12. The compound according to claim 1 , wherein R 9 is alkylsulfanylalkyl, alkylsulfonylalkyl, substituted aryl, substituted arylalkyl or the group A, wherein substituted aryl and substituted arylalkyl are substituted with one to three substituents selected from alkyl, halogen, cyano, alkoxy, alkylsulfanyl and alkylsulfonyl.

13. The compound according to claim 1 wherein R 10 is either pyrazolyl substituted by one alkyl or pyridinyl substituted by one halogen.

14. The compound of claim 11 wherein R 9 is the group A and R 10 is either pyrazolyl substituted by one alkyl or pyridinyl substituted by one halogen.

15. The compound according to claim 1 wherein R 9 is aryl substituted with one to three substituents selected from alkyl, halogen, cyano, alkoxy, alkylsulfanyl and alkylsulfonyl.

16. The compound according to claim 11 wherein R 9 is aryl substituted with one to three substituents selected from alkyl, halogen, cyano, alkoxy, alkylsulfanyl and alkylsulfonyl.

17. The compound according to claim 1 , which compound is selected from the group consisting of:

4-[[5-(1-Methyl-2-oxo-3,4-dihydroquinolin-6-yl)-1H-pyrazol-4-yl]oxy]benzonitrile;

6-[4-(4-Chlorophenoxy)-1H-pyrazol-5-yl]-1-methyl-3,4-dihydroquinolin-2-one;

3-Methoxy-4-[[5-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-1H-pyrazol-4-yl]oxy]benzonitrile;

3-Chloro-4-[[5-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-1H-pyrazol-4-yl]oxy]benzonitrile;

2-Fluoro-4-[[5-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-1H-pyrazol-4-yl]oxy]benzonitrile;

2-Chloro-4-[[5-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-1H-pyrazol-4-yl]oxy]benzonitrile;

6-[4-(3-Chlorophenoxy)-1H-pyrazol-5-yl]-1-methyl-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-(4-methylsulfanylphenoxy)-1H-pyrazol-5-yl]-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-(3-methylsulfanylphenoxy)-1H-pyrazol-5-yl]-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-(3-methylsulfonylphenoxy)-1H-pyrazol-5-yl]-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-(4-methylsulfonylphenoxy)-1H-pyrazol-5-yl]-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-(2-methylsulfanylethoxymethyl)-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

(rac)-1-Methyl-6-[4-(1-methylsulfanylpropan-2-yloxymethyl)-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

1-Methyl-6-[4-(2-methylsulfonylethoxymethyl)-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one;

6-[4-[(4-Methoxyphenyl)methoxy]-1H-pyrazol-3-yl]-1-methyl-3,4-dihydroquinolin-2-one;

6-[4-[[1-(3-Chloropyridine-2-carbonyl)azetidin-3-yl]oxymethyl]-1H-pyrazol-3-yl]-5-fluoro-1-methyl-3,4-dihydroquinolin-2-one; and,

5-Fluoro-1-methyl-6-[4-[[1-(1-methylpyrazole-4-carbonyl)azetidin-3-yl]oxymethyl]-1H-pyrazol-3-yl]-3,4-dihydroquinolin-2-one; or,

a pharmaceutically acceptable salt thereof.

18. A process to prepare a compound according to to claim 1 comprising the reaction of a compound of formula (II) in the presence of hydrazine hydrate;

19. A pharmaceutical composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable carrier, diluent or excipient.